Discover free eBooks, guides and med spa templates on our new resources page

Book a demo
☰
Why us
ICD Hub / Codes for special purposes (U00–U85) / RA03 - Multisystem inflammatory syndrome associated with COVID-19
ICD-11

ICD-11 Codes
for RA03 - Multisystem inflammatory syndrome associated with COVID-19
Teodor Jurukovski January 1, 1970
Fact checked by: Teodor Jurukovski
Use Code

Understanding Multisystem Inflammatory Syndrome Associated with COVID-19

Multisystem inflammatory syndrome associated with COVID-19, identified by the ICD-11 code RA03, is a rare but serious condition that can develop following infection with SARS-CoV-2, the virus responsible for COVID-19. This syndrome is characterized by widespread inflammation affecting various organs and tissues throughout the body. While it predominantly impacts children, presenting as MIS-C (Multisystem Inflammatory Syndrome in Children), a similar condition known as MIS-A (Multisystem Inflammatory Syndrome in Adults) can also occur. Typically, the onset of symptoms occurs several weeks after the initial SARS-CoV-2 infection, which may have been asymptomatic or very mild. This condition requires careful medical evaluation and management.

Recognising the Signs: Symptoms of MIS-C and MIS-A

The presentation of multisystem inflammatory syndrome can vary, but common indicators include a persistent fever lasting more than 24 hours, accompanied by a general feeling of illness and fatigue. Gastrointestinal issues such as abdominal pain, vomiting, and diarrhoea are frequently observed. Mucocutaneous symptoms may include red, bloodshot eyes, and redness or swelling of the lips and tongue. Swelling or redness of the hands and feet, along with skin rashes, can also be present. In more severe cases, individuals may experience trouble breathing, severe stomach pain, confusion, inability to stay awake, or signs of shock. These symptoms necessitate prompt medical attention.

Potential Triggers and Susceptibility Factors

The precise cause of multisystem inflammatory syndrome associated with COVID-19 remains under investigation. However, current understanding suggests it may be an overreaction of the immune system triggered by the SARS-CoV-2 virus. While most children experience mild COVID-19 illness, a small subset develops this inflammatory response. Children, particularly those between the ages of 5 and 11 years, are most commonly affected by MIS-C, though cases have been reported in younger children and adolescents. Adults can also develop MIS-A, sometimes following a less severe or even asymptomatic SARS-CoV-2 infection. Understanding these risk factors is key for early identification.

Diagnostic Pathways for Inflammatory Syndromes

Diagnosing multisystem inflammatory syndrome involves a comprehensive assessment of the patient's symptoms and a process of elimination to rule out other conditions with similar presentations. Healthcare providers will typically conduct tests to confirm or rule out an active SARS-CoV-2 infection, and antibody tests may be used to identify a prior infection. Blood tests are crucial for detecting elevated inflammatory markers and excluding other inflammatory disorders. Imaging studies, such as chest X-rays, echocardiograms, ultrasounds, or CT scans, may be ordered to evaluate the extent of inflammation in specific organs. Accurate diagnosis is vital for appropriate treatment planning.

Managing Inflammatory Responses Post-COVID-19

Treatment for multisystem inflammatory syndrome associated with COVID-19 requires hospitalisation, often in a pediatric intensive care unit for children. Management focuses on reducing inflammation in affected organs and providing supportive care. This may include intravenous fluids, oxygen therapy, medications to support blood pressure and heart function, and in severe respiratory cases, mechanical ventilation. Anti-inflammatory treatments such as steroid therapy and intravenous immunoglobulin (IVIG) are commonly employed. Medications to prevent blood clots may also be prescribed. In critical situations, advanced life support like extracorporeal membrane oxygenation (ECMO) might be necessary. This approach aims to mitigate severe complications.

Alternative Names and Clinical Descriptions

Multisystem inflammatory syndrome associated with COVID-19 (ICD-11 code RA03) is known by several other terms in clinical practice. Common synonyms include MIS-C for the paediatric form and MIS-A for the adult presentation. It may also be referred to as a cytokine storm, a Kawasaki-like syndrome, or Paediatric Inflammatory Multisystem Syndrome (PIMS). These terms reflect the hyperinflammatory state and the diverse organ systems affected by the condition, aiding in broader clinical recognition and documentation.

When to Seek Urgent Medical Attention

Prompt medical evaluation is critical if a child or adult exhibits emergency warning signs of multisystem inflammatory syndrome. These include severe abdominal pain, chest pain or pressure that persists, difficulty breathing, pale or bluish skin, lips, or nail beds, new confusion, or an inability to wake up or stay awake. If any of these severe symptoms are present, immediate emergency department care or calling emergency services is advised. For less severe but concerning symptoms, consulting a healthcare professional without delay is recommended to ensure timely intervention.

Frequently asked questions

What does the ICD-11 code RA03 represent?
ICD-11 code RA03 represents Multisystem inflammatory syndrome associated with COVID-19.
What is the nature of the ICD-11 code RA03?
ICD-11 code RA03 is an emergency code activated for conditions associated with COVID-19.
How is the ICD-11 code RA03 used for documentation?
ICD-11 code RA03 is used for the documentation and reporting of Multisystem inflammatory syndrome associated with COVID-19.
×